Although spontaneous reporting is considered the most effective tool for identifying adverse reactions to known- and clinically significant drugs, in several areas of medicine this method can have limitations linked to the peculiarities of the patients being treated and the drugs used. One such sector is oncology.
The term “herbal” often instinctively arouses an immediate sense of stiffened perplexity, caution, mistrust or complete opposition in pharmacologists as well as clinicians, not least of all because numerous active or non-active destabilising factors are present within in the same botanical species.
Hepatic toxicity of macrolides
An unauthorized user with malicious intent could access the pump remotely and modify the dosage it delivers, which could lead to over- or under-infusion of critical therapies.
L’Agenzia Europea del Farmaco (EMA) ha iniziato una revisione del prodotto medicinale Tysabri (natalizumab) impiegato nel trattamento della Sclerosi Multipla.
L'Agenzia europea per i medicinali (EMA) ha avviato la rivalutazione dei corticosteroidi per via inalatoria per la malattia polmonare cronica ostruttiva
Possibility of a tear on the left atrial wall during use of the device.
L'Agenzia Italiana del Farmaco rende disponibili nuove e importanti informazioni sul rischio di aritmie clinicamente significative quando Harvoni (sofosbuvir + ledipasvir) o Daklinza (daclatasvir) in combinazione con Sovaldi (sofosbuvir) sono somministrati in concomitanza con amiodarone.
La tossicità epatica da macrolidi
80.211.154.110
